

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Ophthalmology

**ESPS manuscript NO:** 16791

**Title:** Pharmacologic vitreolysis: New strategy for treatment of anomalous vitreo-macular adhesion.

**Reviewer's code:** 00505280

**Reviewer's country:** United States

**Science editor:** Yue-Li Tian

**Date sent for review:** 2015-01-29 17:32

**Date reviewed:** 2015-02-23 22:10

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

1. Why is this a challenging new approach? Intravitreal injection is much simpler than vitrectomy. 2. A third factor promoting PVD is weakening of the vitreoretinal adhesion. 3. Why is vitrectomy for V-M traction accompanied by compulsory post-op positioning? 4. Page 8: should be coronary not coronal. 5. When did Jetrea receive FDA approval. 6. Expand on the potential for lens subluxation. Because of findings on animal models, Jetrea should not be administered a second time to the same eye. 7. VMA adhesion of ?1500 um? Or of ?400? 8. Surgery within 1-2 weeks of Jetrea injection? I think that waiting 28 days, like in the MIVI-Trust trials is a more reasonable approach. 9. The final sentence on the Conclusions highly speculative. Do the authors have any data to back up this assertion?

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Ophthalmology

**ESPS manuscript NO:** 16791

**Title:** Pharmacologic vitreolysis: New strategy for treatment of anomalous vitreo-macular adhesion.

**Reviewer's code:** 00505045

**Reviewer's country:** Turkey

**Science editor:** Yue-Li Tian

**Date sent for review:** 2015-01-29 17:32

**Date reviewed:** 2015-02-03 05:54

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

The authors reviewed the current knowledge about the pharmacologic management ways of anomalous vitreo-macular adhesion. This is a nice review with summarized information in this field. Length of review is quite good.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Ophthalmology

**ESPS manuscript NO:** 16791

**Title:** Pharmacologic vitreolysis: New strategy for treatment of anomalous vitreo-macular adhesion.

**Reviewer's code:** 00505066

**Reviewer's country:** China

**Science editor:** Yue-Li Tian

**Date sent for review:** 2015-01-29 17:32

**Date reviewed:** 2015-03-02 18:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

This is a very good review paper. Author reviewed and analyzed many reference and presented several clinical trials of vitreolytic agents as well. Author summarized the current status of investigation on the new approach for the treatment of VMA. It will provide a comprehensive knowledge of non-surgical treatment for anomalous VMA.